32
Session · 32 of 35
Inflammatory Heart Disease
Inflammation is increasingly understood as a unifying mechanism in cardiovascular disease. Sessions cover myocarditis (viral, autoimmune, immune-checkpoint-inhibitor-related), cardiac sarcoidosis, Chagas heart disease, systemic-autoimmune cardiovascular involvement, residual inflammatory risk after ACS (CANTOS, ZEUS, HERMES), and anti-IL-1, anti-IL-6 and colchicine strategies. Discussion includes the diagnostic role of CMR and FDG-PET and the developing inflammation-modulating pipeline.
Topics covered in this session
- Myocarditis (viral, autoimmune, ICI)
- Cardiac sarcoidosis diagnosis
- Chagas heart disease
- Systemic-autoimmune CV involvement
- Anti-IL-1 and anti-IL-6 therapy
- Residual inflammatory risk after ACS
- CMR and FDG-PET imaging
- Inflammation-modulating pipeline
Other Sessions
Explore the full GCCM 2027 program
- 01Interventional Cardiology
- 02Heart Failure & Transplant
- 03Electrophysiology
- 04Preventive Cardiology
- 05Cardio-Oncology
- 06Cardiac Imaging
- 07Digital Cardiology & AI
- 08Cardiometabolic Medicine
- 09Critical Care Cardiology
- 10Structural Heart Disease
- 11Pulmonary Hypertension
- 12Cardiovascular Genomics
- 13Cardiomyopathies
- 14Hypertension
- 15Lipidology
- 16Valvular Heart Disease
- 17Heart Rhythm Disorders
- 18Coronary Artery Disease
- 19Sports Cardiology
- 20Pediatric Cardiology
- 21Geriatric Cardiology
- 22Cardiac Rehabilitation
- 23Congenital Heart Disease
- 24Pericardial Diseases
- 25Cardiovascular Surgery
- 26Vascular & Aortic Diseases
- 27Sudden Cardiac Arrest
- 28Echocardiography
- 29Nuclear Cardiology
- 30Cardiovascular Pharmacology
- 31Women's Cardiovascular Health
- 33Rheumatic Heart Disease
- 34Cardiac Nursing
- 35Global Cardiovascular Health